Anaemia in Nonhaematological Malignancies - A Descriptive Study.

Palaniswamy, R (2010) Anaemia in Nonhaematological Malignancies - A Descriptive Study. Masters thesis, Coimbatore Medical College, Coimbatore.


Download (825kB) | Preview


Incidence Of Malignancies Is On The Rise. Advances In Treatment Protocols Have Resulted In Increased Longevity Of The Patients. Therefore Greater Focus Is Now On Comorbid Conditions, Treatment Of Which Would Improve The Survival And Quality Of Life. Over The Past Decade, There Has Been A Growing Appreciation Of Anaemia As The Source Of A Wide Range Of Symptoms And Poorer Outcomes In Cancer Patients. Data Published On 15 September, 2004 In The European Journal Of Cancer1 (Online Edition) Reveals Two Out Of Three Cancer Patients Suffer From Anaemia And Only 40% Of These Patients Receive Appropriate Treatment (Anaemia Defined As Haemoglobin Less Than 12 G/Dl). Low Haemoglobin Levels Correlate With Poor Quality Of Life And Physical Performance. Performance Status Deteriorates With Decreasing Haemoglobin. This Correlation Remains Regardless Of Disease Status Or Cancer Treatment. J Jaime Caro Et Al2, In Their Systematic And Quantitative Review Of Anaemia As An Independent Prognostic Factor For Survival In Patients With Cancer, Found That Anaemia Was Associated With Shorter Survival Times For Patients With Lung Carcinoma, Cervicouterine Carcinoma, Head And Neck Cancer, Prostatic Carcinoma, Lymphoma And Multiple Myeloma. The Overall Estimated Increase In Risk Of Death Was 65% (54 – 77%). Tumour Hypoxia May Directly Contribute To The Resistance Of The Cancer Patient To Radiation Therapy Or Chemotherapy Via Deprivation Of The Oxygen Essential For The Cytotoxic Actions Of These Agents. Indirectly, Tumour Hypoxia May Contribute To Radioresistance And Chemoresistance By Inducing Proteomic And Genomic Changes That Lead Ultimately To Malignant Progression, With Reduced Local Control And Metastatic Spread, And Ultimately, Increased Resistance And Decreased Survival Time. A Direct Association Between Hypoxia And Anaemia Appears Likely, And Anaemia Is A Modifiable Condition In Many Cancer Patients. This Being The Case, Reducing Tumour Hypoxia By Correcting Anaemia With Recombinant Human Erythropoietin (Rhuepo) And Other Agents Appears To Offer One Possible Therapeutic Option For Enhancing The Effectiveness Of Standard Cancer Therapies3. Hence, It Is Worthwhile To Study The Incidence And Pattern Of Anaemia In Cancer Patients In Our Hospital And Create A Database So That Timely Intervention By The Oncologists With Strategies To Improve The Outcome Of Treatment Can Be Instituted Whenever Anaemia Is Diagnosed.

Item Type: Thesis (Masters)
Uncontrolled Keywords: Anaemia ; Nonhaematological ; Malignancies ; Descriptive Study.
Subjects: MEDICAL > Pathology
Depositing User: Subramani R
Date Deposited: 29 Jun 2017 01:54
Last Modified: 29 Jun 2017 01:54

Actions (login required)

View Item View Item